Discounted Cash Flow (DCF) Analysis Unlevered

Iovance Biotherapeutics, Inc. (IOVA)

$15.82

+0.05 (+0.32%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 15.82 | undervalue

Operating Data

Year
A/P
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 15.82
Beta 0.383
Diluted Shares Outstanding 159.26
Cost of Debt
Tax Rate 1.51
After-tax Cost of Debt 4.27%
Risk-Free Rate
Market Risk Premium
Cost of Equity 6.143
Total Debt 84.45
Total Equity 2,519.48
Total Capital 2,603.92
Debt Weighting 3.24
Equity Weighting 96.76
Wacc

Build Up Free Cash

Year
A/P
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate 0.00%5.31%0.91%4.22%1.51%2.39%2.39%2.39%2.39%2.39%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure -1.20-6.92-46.79-37.57-20.43-----
UFCF ----------
WACC
PV UFCF ----------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 6.08
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -147.28
Equity Value -
Shares Outstanding 159.26
Equity Value Per Share -